Areas covered: Available data on epidemiology, type, and possible risk factors for nephrotoxicity of sofosbuvir-containing treatment are reviewed. Related articles were collected by searching Scopus, Pubmed, and Science direct.
The FDA has approved supplemental application for Harvoni (ledipasvir and sofosbuvir), from Gilead Sciences, to treat hepatitis C virus (HCV)...
The FDA has approved Harvoni (ledipasvir + sofosbuvir) for use in patients with hepatitis C virus (HCV) infection co-infected with...
Areas covered: This is a review of the preclinical and clinical development of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX), an interferon-free, oral, once daily, pangenotypic treatment for chronic HCV infection.
The FDA has approved supplemental applications for Sovaldi (sofosbuvir), from Gilead Sciences, to treat hepatitis C virus (HCV) in children...
Background: Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regimens containing direct-acting antiviral agents (DAAs) have limited retreatment options.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Epclusa (sofosbuvir + velpatasvir), from Gilead Sciences in chronic hepatitis C virus (HCV) infection.
Gilead Sciences has submitted a New Drug Application (NDA) to the FDA for once-daily fixed-dose combination of Sovaldi + GS...
Nucleotide compounds like sofosbuvir, acyclovir, and tenofovir have proven to be amongst the most potent orally available antiviral treatments. These...
The CHMP has given an opinion on the use of a fixed-dose combination of ledipasvir and sofosbuvir from Gilead Sciences...